MedTrace Logo

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

NCT04040361 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-04-06

No results posted yet for this study

Summary

The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab

Conditions

  • Non-small Cell Lung Cancer Stage IB
  • Non-small Cell Lung Cancer Stage II
  • Non-small Cell Lung Cancer Stage ⅢA

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W

DRUG

Ramucirumab

Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W

PROCEDURE

Surgery

Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection

Sponsors & Collaborators

Principal Investigators

  • Masahiro Tsuboi, Dr · National Cancer Center Hospital East

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2022-04-30
Completion
2025-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04040361 on ClinicalTrials.gov